3Hubbard MJ, Cohen P. Trends Biochem Sci, 1993,18: 172- 177.
4Mann M , Ong SE, Gronborg M, et al. Trends Biotechnol, 2002,20: 261 - 268.
5Formman MS, Trojanowski JO, Lee VM. Neurodegenerative diseases: a decade of discoveries the way for therapeutic breakthroughs[J]. Nat Med, 2004,10 (10):1055- 1063.
6Conway KA, Harper JD,Conway KA, Harper JD, Lansbury PT, et al. Biochemistry, 2000,39 : 2552 - 2563.
7Volles, M., and Lansbury, P.J. Zeroing in on the pathogenic form of alpha- synuclein and its mechanism of ncurotoxicity in Parkinson' s disease[J]. Biochemistry, 2003,42:7871 - 7878.
8Abeliovich, A., et al. Mice lacking alpha- synuclein display functional deficits in the nigrostriatal dopamine system[ J]. Neuron, 2000,25 : 239 - 252.
9Nussbaum, R. L., and Polymeropoulos, M.H. Genetics of Parkinson' s disease[J].Hum. Mol. Genet, 1997,6:1687-1691.
10Lee, V. M, and Trojanowski, J.Q. Mechanisms of Parkinson' s disease linked to pathological alpha - synuclein: new targets for drug discovery[J]. Neuron, 2006,52:33 - 38.
